Boehringer Ingelheim is laying off sales reps due to poor U.S. sales of its biosimilar version of Humira. The company will switch to a hybrid sales model. Meanwhile, India faces a crisis over the supply of the polio vaccine as Sanofi has shut down its manufacturing plants in the country. This has raised concerns about a disruption in the country’s immunization campaign. Sanofi is a major supplier of the vaccine, and its closure has impacted over 80% of India’s IPV dose requirements. This news comes as people prepare for the weekend, with activities like reading, spending time outdoors, and watching TV.
Source link
Boehringer Humira biosimilar frustrations, FTC warnings
